Announcement • Aug 07
QT Imaging Holdings, Inc. to Report Q2, 2026 Results on Aug 12, 2026 QT Imaging Holdings, Inc. announced that they will report Q2, 2026 results on Aug 12, 2026 Announcement • Jul 28
QT Imaging Holdings, Inc. Receives Israeli Ministry Of Health Registration For Breast Acoustic CT Scanner QT Imaging Holdings, Inc. announced that the Israeli Ministry of Health has granted registration for the Company's scanner, authorizing commercialization of the system in Israel through February 2, 2028. The approval is based on the Company's existing U.S. FDA clearance and applicable Israeli regulatory requirements. QT Imaging’s Breast Acoustic CT™ Scanner produces true 3D, radiation-free and compression-free images of the breast using low-energy sound waves. The system provides quantitative imaging biomarkers derived from the intrinsic acoustic properties of breast tissue. The system is FDA-cleared as an adjunctive breast imaging device for women 18 years of age and older. The registration also supports QT Imaging's expanding clinical activities through its collaboration with Rambam Health Care Campus, Israel’s leading academic medical center. The planned clinical study will evaluate QT Imaging's Breast Acoustic CT technology in women with hereditary risk for breast cancer. Israel represents an important setting for hereditary breast cancer research because of its established national BRCA1/2 screening program and longstanding expertise in hereditary cancer management. Announcement • Jul 07
QT Imaging Holdings, Inc. Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations QT Imaging Holdings, Inc. announces the successful completion of its first routine inspection by the U.S. Food and Drug Administration (FDA), with zero Form 483 observations. The FDA inspection reviewed QT Imaging’s Quality Management System (QMS) and related processes that support the Company’s operations, with no Form 483 observations issued. The inspector also provided positive feedback regarding the organization of QT Imaging’s QMS and the Company’s responsiveness throughout the inspection process. An FDA Form 483 is issued at the conclusion of an inspection when an FDA investigator has observed conditions that may constitute violations of the Food, Drug and Cosmetic Act and related regulations. The absence of a Form 483 following QT Imaging’s first FDA routine inspection represents an important operational milestone for the Company. Announcement • Jun 23
QT Imaging Holdings, Inc., Annual General Meeting, Jul 28, 2026 QT Imaging Holdings, Inc., Annual General Meeting, Jul 28, 2026. Announcement • May 17
QT Imaging Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $10 million. QT Imaging Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,200,000
Price\Range: $5
Discount Per Security: $0.35
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 800,000
Price\Range: $4.9999
Discount Per Security: $0.349993 Announcement • May 06
QT Imaging Holdings, Inc. to Report Q1, 2026 Results on May 13, 2026 QT Imaging Holdings, Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026 Announcement • Apr 01
QT Imaging Holdings, Inc. Releases Next Generation Breast Imaging Reconstruction Software QT Imaging Holdings, Inc. announced its latest image reconstruction software update release, version 4.5.0. This next-generation software improves spatial resolution in reflection imaging by implementing optimized, spatially varying deconvolution during reflection image reconstruction, resulting in more accurate image representation while maintaining efficient processing times. Version 4.5.0 also introduces enhanced reflection images generated through the fusion of speed of sound and reflection data, providing clinicians and researchers with improved visualization and more comprehensive tissue characterization information. These enhancements are designed to improve image interpretation and support comprehensive and reproducible analysis across a wide range of cases. In addition, the 4.5.0 release includes improved image reconstruction for small breasts and the implementation of more accurate assessment of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and expanding the software’s usability across a broader range of patient anatomies. Building on multimodal imaging approach, advancing the development of attenuation as an additional quantitative biomarker, to complement speed of sound and reflection intensity. The integration of attenuation is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support. These advancements reflect QT Imaging’s continued focus on improving image quality, clinical reliability, and workflow efficiency, and represent another important step in the company’s ongoing development of advanced imaging software solutions. Announcement • Mar 18
QT Imaging Holdings, Inc. to Report Q4, 2025 Results on Mar 25, 2026 QT Imaging Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Mar 25, 2026 Announcement • Mar 11
QT Imaging Holdings, Inc. Receives FDA Clearance for Enhanced Breast Acoustic CT Scanner Configuration QT Imaging Holdings, Inc. announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated configuration of its Breast Acoustic CT scanner, the Company’s 3D ultrasound tomographic breast imaging system. The newly cleared enhanced configuration improves visualization and expands coverage of posterior breast tissue. The updated configuration cleared by the FDA incorporates a tilted transmitter geometry that improves tomographic imaging coverage of breast tissue located near the chest wall, which is an area that can be extremely challenging to capture. This design delivers more complete coverage and improved overall diagnostic utility by optimizing the scanner’s ability to include posterior breast tissue that is often difficult to image with standard approaches. The QTI Breast Acoustic CT scanner generates both reflection-mode and transmission-mode ultrasound data to reconstruct 3D tomographic images. Its proprietary software quantifies fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV), providing valuable insight for breast health assessment and monitoring. Announcement • Feb 24
Qt Imaging Holdings, Inc. Achieves Major Reimbursement Milestone with Ama Category Iii Cpt Code for 3D Breast Ultrasound Tomography QT Imaging Holdings, Inc. announced that the American Medical Association (AMA) CPT (Current Procedural Terminalology) Editorial Panel has approved a new Category III CPTTM code for 3D quantitative transmission volumetric ultrasound tomography of the breast. The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancement of QT Imaging's technology, recognizing the distinct clinical service enabled by its radiation-free, compression-free, 3D breast imaging platform. The new CPT code ensures standardized reporting of this emerging imaging service, supporting data collection, utilization tracking and continued evaluation by clinicians, payers and health systems. The code is scheduled for release on July 1, 2026, with an effective date of January 1, 2027. Category III CPT codes are established by the AMA to track emerging technologies and services that demonstrate clinical relevance and growing adoption. Acceptance of a Category III code signals acknowledgment by the CPT Editorial Panel that a technology represents a distinct and reportable clinical service, and is a major step on the pathway toward broader reimbursement and adoption. QT Imaging's system uses advanced ultrasound tomography to produce true 3D volumetric images of the breast without ionizing radiation or painful compression. The technology is designed to provide quantitative, reproducible information that can be particularly valuable in women with dense breast tissue, while improving the overall patient experience. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. Announcement • Nov 04
QT Imaging Holdings, Inc. to Report Q3, 2025 Results on Nov 11, 2025 QT Imaging Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Nov 11, 2025 Announcement • Oct 03
QT Imaging Holdings, Inc. announced that it expects to receive $18.181197 million in funding QT Imaging Holdings, Inc. announces that it has entered into a securities purchase agreement to issue 12,120,798 common shares at a price of $1.50 per share for gross proceeds of $18,181,197 on October 1, 2025. The closing of the financing is anticipated to be on or before October 3, 2025, subject to customary closing conditions. Notes are issued pursuant to Regulation D. Announcement • Aug 28
QT Imaging Holdings, Inc. Announces Chief Financial Officer Changes QT Imaging Holdings, Inc. announce the appointment of Jay Jennings as its new Chief Financial Officer, with overall responsibility for operational finance, financial reporting, budgeting and strategic planning, and treasury management. Upon his appointment becoming effective on September 2, 2025, Mr. Jennings will succeed the Company’s current CFO, Anastas (Stas) Budagov, who is stepping down to pursue other finance and accounting opportunities. Mr. Jennings has an accomplished history of financial, operational, and strategic leadership success within the digital healthcare and high technology industries. In an executive management career that spans close to 30 years, he has led two go-public transactions, completed various private and public financings, built and managed finance teams ranging up to 100 employees, and been integrally involved in 12 business acquisitions. Mr. Jennings most recently served as Acting Chief Executive Officer and Chief Financial Officer for UpHealth, Inc., a global digital health company. His earlier experience includes executive financial roles at eHealth, Inc., a NASDAQ-listed consumer online marketplace, and MetaCreation Corporation, a NASDAQ-listed developer of visual computing and graphics software and technologies. Prior to launching his corporate career in 1996, Mr. Jennings was an Audit Manager at Ernst & Young, LLP. Mr. Jennings earned a Bachelor of Arts in Economics and Accounting from Claremont McKenna College in 1989. Announcement • Jul 17
QT Imaging Holdings, Inc. Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy QT Imaging Holdings, Inc. announced the launch of its latest QTviewer™?, version 2.8. QTviewer stores and displays the QTscan™? images generated by the Company's U.S. FDA-cleared QTscan™? scanner, the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation -- setting a new standard for safe and repeatable monitoring. Key features of QTviewer 2.8 include: Effortless, Stateless DICOM (Digital Imaging and Communications in Medicine) Viewing: QTviewer 2. 8 enables instant access to QTscan studies without a preconfigured database -- ideal for remote reads, portable drives, or low-resource environments. This also supports direct PACS (Picture Archiving and Communication System) integration where available. Real-Time Lesion Doubling Time Analysis: Integrated tool allows clinicians to assess lesion growth within the standard reading workflow -- enhancing monitoring of disease progression or treatment response. Unlike conventional methods, QT's technology enables fully quantitative, volumetric analysis without the need for contrast agents or ionizing radiation. Advanced Multi-Series Comparison: Radiologists can now view multiple series from the same study in parallel windows, improving anatomical and temporal comparisons. Optimized Viewport Layouts for Radiology Workstations: Vertical orientation and multi-monitor support improve ergonomics and diagnostic clarity for stackable and long-axis views. Secure License Management for Enterprise Use: PC-based license key verification ensures secure, compliant deployment across hospital and academic systems. Improved Stability & Usability: Backend upgrades streamline loading, enhance compatibility, and support quick launches from file associations or command line; and Reinforced Diagnostic Workflow: QTviewer 2.,8 provides automatic recognition of image types, such as speed-of- sound, attenuation, and reflection, ensuring seamless workflow and consistent interpretation. Transforming QTviewer into a precision imaging AI company is a key pillar of the Company's growth strategy. Announcement • Jul 08
QT Imaging Holdings, Inc. Announces Management Appointments QT Imaging Holdings, Inc. announced the appointments of Elaine Iuanow, MD, as Chief Medical Officer and Kim Du as Senior Director of Clinical Operations. These additions to the leadership team significantly enhance the Company’s medical and clinical capabilities as QTI expands its clinical studies as well as the development of AI-driven lesion classification and second-read decision support tools alongside the commercialization of its FDA-cleared QTI Breast Acoustic CT scanner. As CMO, Dr. Iuanow will lead clinical strategy and development, regulatory engagement, and external partnerships with thought leaders and institutions, while supporting QTI’s broader strategic focus of AI-driven precision imaging and diagnostic innovation. A board-certified radiologist with more than two decades of experience in women’s health, breast imaging, and academic medicine, Dr. Iuanow has held clinical positions at Beth Israel Deaconess Medical Center/Harvard Medical School and Brigham and Women's Community Radiology Division. She completed her residency at Tufts Medical Center and a breast imaging fellowship at Faulkner-Sagoff/Brigham and Women’s Hospital. Ms. Du joins QTI with over fifteen years of medical product development experience. Most recently, she served as Senior Director of Clinical Operations for Avisi Technologies, a clinical-stage ophthalmic device company. Prior to Avisi, she held a variety of clinical research management roles at leading medical device innovators, such as Alcon, Avinger and SentreHEART. Ms. Du earned a Bachelor of Science, Bioengineering and Biomedical Engineering from the University of Washington in 2007. As Senior Director of Clinical Operations, Ms. Du is responsible for the strategic leadership and execution of the Company’s clinical trials across all phases of development. She oversees trial planning, site and vendor management, Good Clinical Practice (GCP) compliance, data integrity, and team performance to help ensure the successful execution of studies that support additional regulatory approvals, product adoption, and commercialization. Announcement • Jul 06
QT Imaging Holdings, Inc., Annual General Meeting, Aug 19, 2025 QT Imaging Holdings, Inc., Annual General Meeting, Aug 19, 2025. Announcement • Jul 04
Nasdaq to Delist Common Stock of QT Imaging Holdings The Nasdaq Stock Market announced that it will delist the common stock of QT Imaging Holdings, Inc. QT Imaging’s stock was suspended on January 28, 2025 and has not traded on Nasdaq since that time. Announcement • Jun 25
QT Imaging Holdings, Inc. Announces Latest Image Reconstruction Software Update Release, Version 4.4.0 QT Imaging Holdings, Inc. announced its latest image reconstruction software update release, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency. The software update was developed leveraging NVIDIA’s L40 GPU, powered by the Ada Lovelace architecture. The U.S. FDA-cleared QTI Breast Acoustic CT™ scanner is the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation. Despite the processing speed gains achieved via the version 4.4.0 software update, QTscan breast image fidelity and diagnostic accuracy are uncompromised, and image quality remains best-in-class, with a resolution similar to magnetic resonance imaging (MRI). Designed to meet the needs of busy breast imaging centers, the software update ensures minimal downtime and seamless integration into existing workflows. Accordingly, it enhances scalability for institutions expanding their QTI breast screening programs, ensuring consistent performance across increasing patient volumes. The QTI team continues to innovate by leveraging proprietary machine learning algorithms not only to accelerate image processing via the version 4.4.0 software update, but also to actively reduce scanning time — a key focus area in ongoing development. Version 4.4.0 is optimized for systems utilizing NVIDIA’s L40 GPUs and remains fully backward-compatible with earlier QTI system hardware, ensuring broad accessibility through scalable, software-driven architecture. Announcement • Apr 01
Qt Imaging Inc. Announces Revenue Guidance for the Year 2025 and 2026 QT Imaging Holdings, Inc. announces revenue guidance for the year 2025 and 2026. For 2025, the company is confident in their ability to deliver financial target and generate a revenue of a minimum of $18 million.
For 2026, the company is confident in their ability to deliver financial target and generate a revenue of a minimum of $27 million. Announcement • Jan 30
QT Imaging Holdings, Inc.(OTCPK:QTIH) dropped from S&P TMI Index QT Imaging Holdings, Inc.(OTCPK:QTIH) dropped from S&P TMI Index Announcement • Jan 29
QT Imaging Holdings, Inc.(OTCPK:QTIH) dropped from NASDAQ Composite Index QT Imaging Holdings, Inc removed from NASDAQ Composite Index. Announcement • Jan 15
Qt Imaging Holdings, Inc. Introduces Machine Learning-Enabled Image Interpolation Algorithm to Substantially Reduce Scan Time QT Imaging Holdings, Inc. announced the release of a machine learning-enabled image interpolation algorithm designed to significantly reduce scan times by approximately 50%. This advancement is expected to enhance patient comfort by decreasing time spent on the scanner and improve operational efficiency by increasing the number of patients scanned within a given timeframe. The advanced machine learning algorithm enables sophisticated image interpolation, allowing the system to skip every other scan level while accurately preserving high image quality. This technological breakthrough reduces overall scan time by nearly half without sacrificing diagnostic accuracy, showcasing the ability of QTI's technology to streamline imaging processes, optimize diagnostic workflows, and deliver superior patient outcomes, reinforcing its position at the forefront of medical imaging innovation. The results of this development will be presented for the first time at the SPIE Medical Imaging 2025 conference in San Diego, California. This innovation aligns with QTI's strategy to improve health outcomes by making medical imaging safe, affordable, accessible, and centered on patient experience. The company continues to expand its clinical and research and development efforts, including collaborations with leading institutions such as the National Institutes of Health (NIH), Sunnybrook Health Sciences Centre, and the Stephenson Cancer Center at the University of Oklahoma, to advance precision in cancer detection and treatment. Announcement • Dec 23
QT Imaging Holdings, Inc. Provides Non-Compliance Update As previously announced in a Current Report filed with the Securities and Exchange Commission (the SEC"), on June 17, 2024, the staff of Nasdaq Listing Qualifications (the Staff") notified QT Imaging Holdings, Inc. (the Company") that the bid price of its common stock, par value $0.0001 per share, (the Common Stock") had closed at less than $1 per share over the previous thirty (30) calendar days, and, as a result, did not comply with Listing Rule 5450(a)(1) of the Nasdaq Listed Company Manual (the Price Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided with 180 calendar days, or until December 16, 2024, to regain compliance with the Price Rule. Subsequently, and as previously announced in a Current Report filed with the SEC on November 12, 2024, the Staff notified the Company on November 6, 2024 that it had determined to commence proceedings to delist the Common Stock from the Nasdaq Global Select Market (the Nasdaq") due to its determination that the Company's common stock is no longer suitable for listing because the Company's market value of is listed securities fell below the minimum $50,000,000 required for continued listing as set in Rule 5450(b)(2)(A) (the MVLS Rule") and the Company was unable to regain compliance with the MVLS Rule by November 4, 2024. The Company proceeded to initiate an appeal of the Staff's determination to commence delisting of the Common Stock from the Nasdaq, requesting that the matter be submitted to a Hearings Panel (the Panel") per the procedures set in the Nasdaq Listing Rule 5800 Series, staying the suspension of the Company's securities and the filing of a Form 25-NSE by the Staff pending the Panel's decision. On December 17, 2024, the Staff formally notified the Company that it was unable to regain compliance with the Price Rule during the provided 180-day compliance window, which the Staff considers an additional basis for delisting the Company's Common Stock from the Nasdaq and which will be considered in the Panel's rendering of a decision on the Company's appeal. If the Company's appeal is unsuccessful, it is expected that the Common Stock would be delisted from the Nasdaq, in which case, the Company may apply to list on a different listing tier of the Nasdaq Global Stock Market or apply to list the Common Stock on the over-the-counter market. The over-the-counter market is a significantly more limited market than the Nasdaq. The transition of the Common Stock to the over-the-counter market will not affect the Company's business operations or its reporting requirements under the rules of the SEC. Announcement • Sep 11
QT Imaging Holdings Receives Non-Compliance Notice Regarding Nasdaq Market Value of Publicly Held Securities Rule As previously disclosed by QT Imaging Holdings, Inc. in a Current Report on Form 8 K filed with the U.S. Securities and Exchange Commission on May 10, 2024, the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the 30 consecutive business days prior to May 6, 2024, the Company's Market Value of Listed Securities (MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement"). In addition, as previously disclosed by the Company in a Current Report on Form 8-K filed with the SEC on June 21, 2024, the Staff of Nasdaq on June 17, 2024 sent to the Company a further written notice notifying the Company that it is also no longer in compliance with the Nasdaq Listing Rules because the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days (the minimum bid price requirement"). On September 4, 2024, the Company received a further written notice (the Notice") from the Staff of Nasdaq notifying the Company that, for the prior 31 consecutive business days, the Company's Market Value of Publicly Held Securities (MVPHS") was below the minimum of $15 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(c) (the MVPHS Requirement"). The Notice has no immediate effect on the listing of the Company's common stock on The Nasdaq Global Market at this time. An indicator reflecting non compliance will be displayed with quotation information related to the Company's shares on NASDAQ.com and NASDAQTrader.com and may be displayed by other third-party providers of market data information. The Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(D) (the Compliance Period Rule"), the Company has a period of 180 calendar days from the date of the Notice, or until March 3, 2025 (the Compliance Date"), to regain compliance with respect to the MVPHS Requirement. During this period, and subject to the notices that the Company received from the Staff of Nasdaq on May 10, 2024 and June 17, 2024 with respect to the MVLS Requirement and the minimum bid price requirement, respectively, the Company's securities will continue to trade on The Nasdaq Global Market under the symbol QTI". If at any time before the Compliance Date the Company's MVPHS closes at or above $15 million for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it has regained compliance with the MVPHS Requirement and will close the matter. If the Company does not regain compliance with the MVPHS Requirement by the Compliance Date, the Staff will provide a written notification to the Company that its securities are subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearings Panel (the Panel"). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful. The Company intends to monitor its MVPHS between now and the Compliance Date and may, if appropriate, consider available options to regain compliance with the MVPHS Requirement. Additionally, the Company may consider applying to transfer the listing of its securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). However, there can be no assurance that the Company will be able to regain or maintain compliance with Nasdaq listing criteria. New Risk • Aug 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.1m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$6.2m). Shareholders have been substantially diluted in the past year (124% increase in shares outstanding). Minor Risks Revenue is less than US$5m (US$3.1m revenue). Market cap is less than US$100m (US$10.8m market cap). Reported Earnings • Aug 09
Second quarter 2024 earnings released Second quarter 2024 results: US$0.30 loss per share. Net loss: US$6.43m (flat on 2Q 2023). Announcement • Jun 23
QT Imaging Holdings Receives a Further Written Notice from Nasdaq Due to Non-Compliance with the Nasdaq Listing Rules Related to Minimum Bid Price of the Common Stock As previously disclosed by QT Imaging Holdings, Inc. (the ‘Company’) in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on May 10, 2024, the Company received a written notice from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the 30 consecutive business days prior to May 6, 2024, the Company’s Market Value of Listed Securities (‘MVLS’) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the ‘MVLS Requirement’). On June 17, 2024, the Staff of Nasdaq sent to the Company a further written notice (the ‘Notice’) notifying the Company that it is also no longer in compliance with the Nasdaq Listing Rules because the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days . The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. An indicator reflecting non-compliance will be displayed with quotation information related to the Company’s shares on NASDAQ.com and NASDAQTrader.com and may be displayed by other third-party providers of market data information. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Notice, or until December 16, 2024 (the ‘Compliance Date’), to regain compliance with the minimum bid price requirement. This compliance period expires after the date when compliance period to regain compliance with respect to the MVLS Requirement expires, which is November 4, 2024. During the period from the receipt of the Notice until the Compliance Date, the Company’s securities will continue to trade on The Nasdaq Global Market under the symbol ‘QTI.’ If at any time before the Compliance Date the bid price for the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide written notification to the Company that it has regained compliance with the minimum bid price requirement. In the event the Company does not regain compliance with the minimum bid price requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period if it transfers to The Nasdaq Capital Market, provided that it meets the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the minimum bid price requirement) based on the Company’s most recent public filings and market information and provides written notice to Nasdaq of its intention to cure the bid price deficiency during the additional compliance period. If the Company fails to regain compliance during the compliance period (including a second compliance period, if applicable), then Nasdaq will notify the Company of its determination to delist its common stock, at which point the Company may appeal Nasdaq’s delisting determination to a Nasdaq hearing panel. The Company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance with the minimum bid price requirement, which may include effecting a reverse stock split. Additionally, the Company may consider applying to transfer the listing of its securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-calendar day compliance period, secure an additional 180 calendar day period to regain compliance, maintain compliance with the other Nasdaq listing requirements or be successful in appealing any delisting determination. Announcement • May 11
QT Imaging Holdings Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5450(b)(2)(A) On May 6, 2024, QT Imaging Holdings, Inc. (the ‘Company’) received a written notice (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (‘MVLS’) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the ‘MVLS Requirement’). The Nasdaq Notice has no immediate effect on the listing of the Company’s shares on The Nasdaq Global Market at this time. An indicator reflecting non-compliance will be displayed with quotation information related to the Company’s shares on NASDAQ.com and NASDAQTrader.com and may be displayed by other third-party providers of market data information. The Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C) (the ‘Compliance Period Rule’), the Company has a period of 180 calendar days from the date of the Notice, or until November 4, 2024 (the ‘Compliance Date’), to regain compliance with respect to the MVLS Requirement. During this period, the Company’s securities will continue to trade on The Nasdaq Global Market under the symbol ‘QTI’. If at any time before the Compliance Date the Company’s MVLS closes at or above $50 million for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it has regained compliance with the MVLS Requirement and will close the matter. If the Company does not regain compliance with the MVLS Requirement by the Compliance Date, the Staff will provide a written notification to the Company that its securities are subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel (the ‘Panel’). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful. The Company intends to monitor its MVLS between now and the Compliance Date and may, if appropriate, consider available options to regain compliance with the MVLS Requirement. Additionally, the Company may consider applying to transfer the listing of its securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). However, there can be no assurance that the Company will be able to regain or maintain compliance with Nasdaq listing criteria. Announcement • Apr 18
QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis QT Imaging Holdings, Inc. announced positive data regarding the diagnostic performance of QTI’s Breast Acoustic CTTM Scans for mass detection from its second blinded multi-reader multi-case study. The study was published in Academic Radiology, online, in January 2024: A Multireader Multicase (MRMC) Receiver Operating Characteristic (ROC) Study Evaluating Noninferiority of Quantitative Transmission (QT) Ultrasound to Digital Breast Tomosynthesis (DBT) on Detection and Recall of Breast Lesions - Academic Radiology. Twenty-four breast radiologists participated in a study of 177 selected cases (66 with cancer, atypia, or solid mass and 111 normal or with nonsolid benign abnormality). The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05. This means that QTI technology is non-inferior to DBT in the detection of breast lesions as a whole, with high specificity in determining benign cysts and thus decreasing benign recall rates. Statistical analysis was performed by Dr. Yulei Jiang from the Department of Radiology of the University of Chicago. While fewer than 5% of women with breast cancer are diagnosed before the age of 40(1), those cancers are usually aggressive, and the young patients suffer from poor survival outcomes. Unfortunately, routine screening mammograms are not recommended for women under 40 because risks outweigh potential benefits at this young age. Fortunately, the now published results suggest that QTI’s technology can be a much-needed potential alternative to mammography for women too young to undergo mammography screening. Announcement • Mar 20
QT Imaging Holdings, Inc. Announces Chief Executive Officer Changes QT Imaging Holdings, Inc. announced that the Board of Directors has appointed former GigCapital5, Inc. CEO Dr. Raluca Dinu as Active Chief Executive Officer, effective March 12, 2024. Dr. Dinu will serve in this position for one year, when the Company will reevaluate this strategic position. Dr. John Klock will step down as Chief Executive Officer, but will remain part of the Board of Directors, transitioning to serve as a Company advisor. Dr. Dinu served as a senior executive in small and large size public companies, has a global, operationally focused business background, public company governance experience, delivered strong results in turnaround and M&A situations, lead strategic growth, and consolidation in fast-paced business environments. Dr. Raluca Dinu is on the board of numerous public traded companies and philanthropic organizations and has co-founded five Private-to-Public Equity (PPE) companies, which acquire late-stage private companies for the purpose of taking them public on their continuous growth journey. New Risk • Mar 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 103% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.1m free cash flow). Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-US$4.5m). Revenue has declined by 95% over the past year. Shareholders have been substantially diluted in the past year (103% increase in shares outstanding). Revenue is less than US$1m (US$37k revenue). Minor Risk Market cap is less than US$100m (US$26.2m market cap). Board Change • Mar 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
